The Bruton’s tyrosine kinase (BTK) inhibitors market was valued at USD 10.48 billion in 2024. It is projected to grow at an 8.00% CAGR during 2025–2034, reaching USD 22.63 billion by 2034, supported by rising cases of mantle cell lymphoma. BTK inhibitors are widely used for treating this indication. https://www.expertmarketresearch.com/reports/brutons-tyrosine-kinase-btk-inhibitors-market